ERK1/2 anticorps

N° du produit ABIN1724731

Détail du produit anti-ERK1/2 anticorps

Antigène: ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ERK1/2 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Fonction: p44/42 MAPK (Erk1/2) Antibody

Purification: Ascitic fluid

Immunogène: Purified recombinant fragment of human MAPK expressed in E. Coli.

Clone: 3F8

Isotype: IgG2b

Information d'application

Indications d'application:

ELISA: 1/10000

FCM: 1/200 - 1/400

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Références pour anticorps anti-ERK1/2 (ABIN1724731)

Lønne, Masoumi, Lennartsson, Larsson: "Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway." dans: The Journal of biological chemistry, Vol. 284, Issue 48, pp. 33456-65, (2009) (PubMed).

Détails sur ERK1/2

Antigène: ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))

Autre désignation: p44/42 MAPK (Erk1/2) (MAPK1/3 Produits)

Synonymes: anticorps erk1/2, anticorps mitogen-activated protein kinase, anticorps erk1/2

Sujet:

Description: Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines and is an important target in the diagnosis and treatment of cancer. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs, along with MEK inhibitors such as U0126 and PD98059.

Aliases: ERK, p38, p40, p41, ERK2, ERT1, MAPK2, PRKM1, PRKM2, P42MAPK, p41mapk, MAPK1

Poids moléculaire: 42kDa

ID gène: 5594

HGNC: 5594

UniProt: P28482